AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

NZ sharemarket up 0.3% after three falls
Markets Market close

NZ sharemarket up 0.3% after three falls

The S&P/NZX 50 Index closed at 12,761.35, gaining 37.98 points or 0.3%.

Winton 'stands to gain millions': MP
Property

Winton 'stands to gain millions': MP

The proposed fast-tracking of Sunfield is 'cronyism', local MP claims.

ForBarr raises Hallenstein Glasson target price 20%
Retail

ForBarr raises Hallenstein Glasson target price 20%

The outlook in the golden country is golden, they say.